Literature DB >> 15824914

Are incorrectly used drugs more frequently involved in adverse drug reactions? A prospective study.

A P Jonville-Béra1, F Béra, E Autret-Leca.   

Abstract

OBJECTIVES: The aims of this study were to identify and evaluate the frequency of drugs involved in adverse drug reactions (ADRs) for which recommendations of the Summary of Product Characteristics (SPC) had not been respected and to compare the percentages of drugs suspected of being the cause of ADRs when correctly and incorrectly used.
METHODS: All ADRs reported to the Regional Pharmacovigilance Centre of Tours (RPC) over a period of 5 months were analysed to identify drugs used "incorrectly" defined by drug use beyond the recommendations of the SPC, i.e. drugs used when contra-indicated and/or drugs used for an off-label indication, and/or drugs used at an inappropriate dose, and/or inappropriate duration of treatment, and/or drugs used in the presence of a potentially or definitely interacting drug.
RESULTS: Included in the study were 182 ADRs involving 182 patients. Of 642 drugs, 169 (26%) were incorrectly used and for 81 patients (44.5%) ADRs involved at least one "incorrectly" used drug. These included 10% (64 of 642) drug interactions, 7.3% (47 of 642) off-licence indications, 5% (32 of 642) inadequate dosage, 3% (20 of 642) incorrect duration of treatment and 1% (6 of 642) contraindications. "Correctly" used drugs appeared to be less often the cause of the ADRs than "incorrectly" used drugs (59.4% versus 75%, P=0.0001).
CONCLUSION: "Incorrectly" used drugs were more often causally linked to ADR than correctly used drugs. A meaningful number of ADRs could probably be avoided if SPC guidelines for a safe and effective drug use are carefully adhered to.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15824914     DOI: 10.1007/s00228-004-0881-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  A novel scheme for the reporting of adverse drug reactions.

Authors:  A Clarkson; E Ingleby; I Choonara; P Bryan; P Arlett
Journal:  Arch Dis Child       Date:  2001-04       Impact factor: 3.791

Review 2.  Unlicensed and off-label drug use in children: implications for safety.

Authors:  Imti Choonara; Sharon Conroy
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  [Preventability of adverse effects in a medical emergency service].

Authors:  P Olivier; O Boulbès; M Tubery; P Carles; J L Montastruc; M Lapeyre-Mestre
Journal:  Therapie       Date:  2001 May-Jun       Impact factor: 2.070

4.  Off-label prescribing in oncology.

Authors:  Susan G Poole; Michael J Dooley
Journal:  Support Care Cancer       Date:  2004-02-18       Impact factor: 3.603

5.  Focusing on the preventability of adverse drug reactions.

Authors:  G T Schumock; J P Thornton
Journal:  Hosp Pharm       Date:  1992-06

6.  Off-label drug use in human immunodeficiency virus disease.

Authors:  C L Brosgart; T Mitchell; E Charlebois; R Coleman; S Mehalko; J Young; D I Abrams
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-05-01

7.  Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study.

Authors:  S Turner; A J Nunn; K Fielding; I Choonara
Journal:  Acta Paediatr       Date:  1999-09       Impact factor: 2.299

8.  Factors associated with preventable adverse drug reactions.

Authors:  T F Pearson; D G Pittman; J M Longley; Z T Grapes; D J Vigliotti; S R Mullis
Journal:  Am J Hosp Pharm       Date:  1994-09-15

Review 9.  Epidemiology of drug-drug interactions as a cause of hospital admissions.

Authors:  C A Jankel; L K Fitterman
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

10.  Adverse drug reactions in a paediatric intensive care unit.

Authors:  A M Gill; H J Leach; J Hughes; C Barker; A J Nunn; I Choonara
Journal:  Acta Paediatr       Date:  1995-04       Impact factor: 2.299

View more
  19 in total

Review 1.  [Off-label therapy: current problems from the perspective of the Pharmaceutical Commission of the German Medical Profession].

Authors:  R W C Janzen; W D Ludwig
Journal:  Z Rheumatol       Date:  2012-02       Impact factor: 1.372

2.  Off label and unlicensed drugs use in paediatric cardiology.

Authors:  M Bajcetic; M Jelisavcic; J Mitrovic; N Divac; S Simeunovic; R Samardzic; R Gorodischer
Journal:  Eur J Clin Pharmacol       Date:  2005-09-08       Impact factor: 2.953

Review 3.  Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature.

Authors:  Jennifer Mason; Munir Pirmohamed; Tony Nunn
Journal:  Eur J Clin Pharmacol       Date:  2011-07-22       Impact factor: 2.953

Review 4.  Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response.

Authors:  Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Bruno Flamion; Lars L Gustafsson; Hubert Leufkens; Malcolm Rowland; Christian K Schneider; Brigitte Bloechl-Daum
Journal:  Nat Rev Drug Discov       Date:  2011-07-01       Impact factor: 84.694

Review 5.  Two decades of off-label prescribing in children: a literature review.

Authors:  Shamala Balan; Mohamed Azmi Ahmad Hassali; Vivienne S L Mak
Journal:  World J Pediatr       Date:  2018-09-14       Impact factor: 2.764

6.  Preventability analysis of adverse drug reactions detected in two internal medicine departments in Romania.

Authors:  Andreea Farcas; Camelia Bucsa; Aura Sinpetrean; Daniel Leucuta; Cristina Mogosan; Dan Dumitrascu; Andrei Cadariu Achimas; Marius Bojita
Journal:  Intern Emerg Med       Date:  2012-08-21       Impact factor: 3.397

Review 7.  Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review.

Authors:  Joana Magalhães; António Teixeira Rodrigues; Fátima Roque; Adolfo Figueiras; Amílcar Falcão; Maria Teresa Herdeiro
Journal:  Eur J Clin Pharmacol       Date:  2014-10-16       Impact factor: 2.953

8.  Drug related problems and off-label drug treatment in children as seen at a drug information centre.

Authors:  Elin Kimland; Ulf Bergman; Synnöve Lindemalm; Ylva Böttiger
Journal:  Eur J Pediatr       Date:  2006-12-29       Impact factor: 3.183

9.  Off-label drug prescribing in a Portuguese paediatric emergency unit.

Authors:  Marina Ribeiro; Arminda Jorge; Ana Filipa Macedo
Journal:  Int J Clin Pharm       Date:  2012-09-28

10.  Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment.

Authors:  McKee J McClendon; Santiago Hernandez; Kathleen A Smyth; Alan J Lerner
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.